R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Paves the way for next-gen ultra-precise gas sensing
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Subscribe To Our Newsletter & Stay Updated
